Clinical trial
A Phase 1-2, Multicenter, Open-Label Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer
NCT00558922 is registered in ClinicalTrials.gov with Aegera Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1-2, Multicenter, Open-Label Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer
- Lead sponsor
- Aegera Therapeutics
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- September 30, 2007
- Completion date
- October 31, 2009
- Enrollment
- 54 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.